Compare Charles River Laboratories Intl. Inc (CRL) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs SiTime Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while SiTime Corporation trades at $678.91 (market cap $20.05B). The key difference: SiTime Corporation is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| CRL | SITM | |
|---|---|---|
Market Cap | $13.46B | $20.05B |
Sector | Health | Technology |
52-Week High | $282.00 | $901.60 |
52-Week Low | $145.57 | $212.77 |
Enterprise Value | $16.30B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
SITM trades at $700.42, up 1.52% today, with a bullish technical outlook and strong analyst consensus. Recent Q2 2026 earnings beat estimates with EPS of $2.34 versus $1.95 expected, driven by 127% revenue growth from AI infrastructure demand. The stock shows robust institutional interest and positive media coverage highlighting AI timing growth.
Outlook is positive with a consensus price target of $870, but risks include high valuation multiples (P/E 1,111.15, P/S 38.1) and integration challenges from the Renesas acquisition. Earnings momentum and AI exposure support upside, yet execution and premium pricing warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
